French healthcare company Sanofi S.A. (Euronext Paris:SAN) (Nasdaq:SNY) reported on Tuesday that its investigational candidate lunsekimig met primary and key secondary endpoints in phase 2 studies in asthma and chronic rhinosinusitis with nasal polyps (CRSwNP), while results were mixed in atopic dermatitis.

The company said that lunsekimig, a bispecific Nanobody targeting TSLP and IL-13, was well tolerated across all trials with an acceptable safety profile.

In the AIRCULES phase 2b study, lunsekimig demonstrated statistically significant reductions in exacerbations and improvements in lung function in moderate-to-severe asthma patients, regardless of biomarker status. The DUET phase 2a study also met its primary and key secondary endpoints, showing improvements in nasal polyp score, congestion, and imaging metrics versus placebo at Week 24.

Meanwhile, the exploratory VELVET phase 2b study in atopic dermatitis did not meet its primary endpoint, although improvements were observed in secondary measures of skin clearance.

Across all studies, adverse event rates and discontinuations were comparable to placebo, with commonly reported events including respiratory infections and injection site reactions.

Sanofi intends to present detailed results at upcoming medical congresses.

Lunsekimig remains in clinical development, including ongoing phase 2 and phase 3 programmes, and has not yet been evaluated by regulatory authorities.